ARMP צמיחת רווח למניה משנה לשנה בשנים עשר החודשים האחרונים Armata

Full capacity utilization of phage synthesis laboratories is driving growth, as evidenced by this GURU.Markets chart: quarterly EPS dynamics are currently 68.00 hitting a new level. The business potential is based on the sale of treatments against superbugs. Furthermore, intellectual capital and patents for rare drugs create a solid foundation for the future monetization of Armata Pharmaceuticals (ARMP).

Quarterly EPS growth measures the dynamics of net profit per share, allowing for an assessment of business efficiency compared to previous periods. This metric calculates the percentage change in earnings, filtering out market noise from actual financial results. The current quarterly EPS variability is 68.00. For Armata Pharmaceuticals (ARMP), this indicator is critical as it reflects the cost of developing phage-based drugs. High FDA certification costs render profits volatile until clinical trials are completed.